Business Context and Reporting Period
This Form 8-K filing by Cocrystal Pharma, Inc. covers the reporting period of November 22, 2014. The report addresses corporate governance changes specifically tied to the company's entry into an Agreement and Plan of Merger with RFS Pharma, LLC.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and merger-related disclosures rather than financial performance.
Material Changes
- Board Resignations: On November 22, 2014, Dr. Roger Kornberg and Dr. Sam Lee resigned from the Board of Directors.
- Mergers and Acquisitions: The resignations occurred in connection with the Company's entry into a Merger Agreement with RFS Pharma, LLC, dated November 25, 2014.
Outlook, Risks, and Management Commentary
Management indicates that the Merger Agreement was disclosed in a press release issued on November 25, 2014. Further details regarding the transaction are expected to be provided in a subsequent Current Report on Form 8-K filed on December 1, 2014. No specific risks, contingencies, or unusual items were detailed in this specific filing text.
Key Facts for Investor Verification
- Verify the terms of the Merger Agreement with RFS Pharma, LLC as detailed in the upcoming December 1, 2014, Form 8-K filing.
- Confirm the composition of the Board of Directors following the resignations of Dr. Kornberg and Dr. Lee.
- Review the November 25, 2014, press release for initial details on the merger transaction.